Trump nominates Martin Makary to head FDA

US President-elect Donald Trump has named Johns Hopkins surgical oncologist Marty Makary as his nominee for Commissioner of the Food and Drug Administration (FDA), confirming recent speculation that he was the frontrunner for the position.

This latest health associated nomination comes in the wake of Mr Trump’s recent choice earlier this month of the well-known vaccine sceptic Robert F Kennedy Jr to be the Secretary of the Department of Health and Human Services(HHS), which has come under considerable criticism and caused a crisis for vaccine developer. The FDA is part of the HHS Department.

For his part, Dr Makary has been a critic of how the US handled the pandemic response, although he describes himself as pro-vaccine. However, he did oppose broad vaccine mandates and criticized COVID vaccination policies for young adults and children.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical